After the publication of these guidelines Rydén and colleagues expressed certain concerns on these suggestions and presented an update on ESC HF guidelines: “DPP-4 inhibitors (gliptins) increase plasma levels of incretins by inhibiting their breakdown, thereby augmenting insulin release. This evidence concerns the gene INS and hydrops fetalis.